News

Published on 4 Oct 2021 on Insider Monkey via Yahoo Finance

Is Trean Insurance Group, Inc. (TIG) Going to Burn These Hedge Funds?


Article preview image

Hedge Funds and other institutional investors have just completed filing their 13Fs with the Securities and Exchange Commission, revealing their equity portfolios as of the end of June. At Insider Monkey, we follow nearly 900 active hedge funds and notable investors and by analyzing their 13F filings, we can determine the stocks that they are collectively bullish on. One of their picks is Trean Insurance Group, Inc. (NASDAQ:TIG), so let’s take a closer look at the sentiment that surrounds it in the current quarter.

Trean Insurance Group, Inc. (NASDAQ:TIG) was in 10 hedge funds' portfolios at the end of June. The all time high for this statistic is 14. TIG investors should pay attention to a decrease in hedge fund interest of late. There were 11 hedge funds in our database with TIG holdings at the end of March. Our calculations also showed that TIG isn't among the 30 most popular stocks among hedge funds (click for Q2 rankings).

In the financial world there are a large number of tools investors have at their disposal to grade stocks. A pair of the most under-the-radar tools are hedge fund and insider trading indicators. We have shown that, historically, those who follow the top picks of the best fund managers can outperform the broader indices by a solid amount. Insider Monkey's monthly stock picks returned 185.4% since March 2017 and outperformed the S&P 500 ETFs by more than 79 percentage points (see the details here). That's why we believe hedge fund sentiment is a useful indicator that investors should pay attention to.

NYSE.AMRX price evolution
NASDAQ.ATOS price evolution

Want to become a better investor?

Start tracking your investments with Statfolio

Sign up for free
Related News
Amneal Pharmaceuticals Inc (AMRX) Q3 2024 Earnings Call Highlights: Strong...

Release Date: November 08, 2024 For the complete transcript of the earnings call, please refer to...

GuruFocus.com · via Yahoo Finance 10 Nov 2024

Generic Drug-Focused Amneal Beats Q3 Expectations, Reaffirms Annual Forecasts

On Friday, Amneal Pharmaceuticals Inc (NASDAQ:AMRX) reported third-quarter adjusted EPS of $0.16,...

Benzinga · via Yahoo Finance 8 Nov 2024

Earnings To Watch: Amneal Pharmaceuticals Inc (AMRX) Reports Q3 2024 Result

Amneal Pharmaceuticals Inc (NASDAQ:AMRX) is set to release its Q3 2024 earnings on Nov 8, 2024. T...

GuruFocus.com · via Yahoo Finance 7 Nov 2024

Amneal Pharmaceuticals Inc (AMRX) Q2 2024 Earnings Call Highlights: Strong...

Q2 Revenue: $702 million, a growth of 17%. Generics Net Revenue: $427 million, up 14%. Biosimilar...

GuruFocus.com · via Yahoo Finance 11 Oct 2024

Insider Sale at Amneal Pharmaceuticals Inc (AMRX): Executive Vice President...

The transaction was documented in a recent SEC Filing. Following this sale, the insider now owns...

GuruFocus.com · via Yahoo Finance 24 Aug 2024

Insider Sale at Amneal Pharmaceuticals Inc (AMRX) by Executive Vice President...

Following this transaction, the insider now owns 256,670 shares of Amneal Pharmaceuticals Inc....

GuruFocus.com · via Yahoo Finance 8 Aug 2024

Insider Sale: Director Deborah Autor Sells 38,000 Shares of Amneal Pharmaceuticals Inc (AMRX)

On May 17, 2024, Deborah Autor, Director at Amneal Pharmaceuticals Inc (NASDAQ:AMRX), executed a ...

GuruFocus.com via Yahoo Finance 22 May 2024

Amneal Pharmaceuticals, Inc. (NYSE:AMRX) Q1 2024 Earnings Call Transcript

Amneal Pharmaceuticals, Inc. (NYSE:AMRX) Q1 2024 Earnings Call Transcript May 3, 2024 Amneal Phar...

Insider Monkey via Yahoo Finance 4 May 2024

Drugmaker Amneal agrees to $270 million U.S. opioid settlement

, opens new tab said on Friday it had reached a deal valued at more than $270 million to resolve...

Reuters 3 May 2024

Amneal stock climbs on Q1 report, opioid settlement update (NASDAQ:AMRX)

Amneal (AMRX) stock climbed 9% Friday after the drugmaker released its Q1 earnings report and sai...

Seeking Alpha 3 May 2024